Portal de Periódicos da CAPES

COVID‐19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report

2021; Wiley; Volume: 196; Issue: 3 Linguagem: Inglês

10.1111/bjh.17890

1365-2141

Massimo Breccia, Elisabetta Abruzzese, Vincenzo Accurso, Immacolata Attolico, Sara Barulli, Micaela Bergamaschi, Gianni Binotto, Monica Bocchia, Massimiliano Bonifacio, Giovanni Caocci, Isabella Capodanno, Fausto Castagnetti, Francesco Cavazzini, Elena Crisà, Monica Crugnola, Maria Stella De Candia, Chiara Elena, Carmen Fava, Sara Galimberti, Antonella Gozzini, Gabriele Gugliotta, Tamara Intermesoli, Alessandra Iurlo, Gaetano La Barba, Roberto Latagliata, Sabrina Leonetti Crescenzi, Luciano Levato, Giuseppina Loglisci, Alessandro Lucchesi, Luigiana Luciano, Francesca Lunghi, Debora Luzi, Malato Alessandra, Maria Cristina Miggiano, Pizzuti Michele, Patrizia Pregno, Davide Rapezzi, Giovanna Rege‐Cambrin, Gianantonio Rosti, Sabina Russo, Rosaria Sancetta, Anna Rita Scortechini, Federica Sorà, Paolo Sportoletti, Fabio Stagno, Agostino Tafuri, Mario Tiribelli, Robin Foà, Giuseppe Saglio,

COVID-19 Clinical Research Studies

Summary Limited information is available on the impact of the COVID‐19 pandemic on the management of chronic myeloid leukaemia (CML). The Campus CML network collected retrospective information on 8 665 CML patients followed at 46 centres throughout Italy during the pandemic between February 2020 and January 2021. Within this cohort, we recorded 217 SARS‐CoV‐2‐positive patients (2·5%). Most patients (57%) were diagnosed as having SARS‐CoV‐2 infection during the second peak of the pandemic (September 2020 to January 2021). The majority (35%) was aged between 50 and 65 years with a male prevalence (73%). Fifty‐six percent of patients presented concomitant comorbidities. The median time from CML diagnosis to SARS‐CoV‐2 infection was six years (three months to 18 years). Twenty‐one patients (9·6%) required hospitalization without the need of respiratory assistance, 18 (8·2%) were hospitalized for respiratory assistance, 8 (3·6%) were admitted to an intensive care unit, while 170 (78%) were only quarantined. Twenty‐three percent of patients discontinued tyrosine kinase inhibitor (TKI) therapy during the infection. Twelve patients died due to COVID‐19 with a mortality rate of 5·5% in the positive cohort and of 0·13% in the whole cohort. We could also document sequelae caused by the SARS‐CoV‐2 infection and an impact of the pandemic on the overall management of CML patients.